Point-of-care testing for early diagnosis and population screening of Alzheimer’s disease: Recent advances and perspectives
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Dementia and Cognitive Impairment Research · SARS-CoV-2 detection and testing · Clinical Laboratory Practices and Quality Control
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Alzheimer’s disease10.1016/S0140-6736(20)32205-4 ↗
2. 2024 Alzheimer’s disease facts and figures, Alzheimers Dement. 20 (2024) 3708–3821. https://doi.org/10.1002/alz.13809.10.1002/alz.13809 ↗
3. Dementia statistics, Alzheimers Dis. Int. (n.d.). 〈https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/〉 (accessed February 27, 2026).
4. The amyloid hypothesis of Alzheimer’s disease at 25 years10.15252/emmm.201606210 ↗
5. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies10.1038/s41392-024-01911-3 ↗
6. Reversing synapse loss in Alzheimer’s disease: rho-guanosine triphosphatases and insights from other brain disorders10.1007/s13311-014-0328-4 ↗
7. Potential impact of slowing disease progression in early symptomatic Alzheimer’s Disease on patient quality of life, caregiver time, and total societal costs: estimates based on findings from GERAS-US study10.3233/JAD-231166 ↗
8. Alzheimer’s disease: The right drug, the right time10.1126/science.aau0437 ↗
9. Age-dependent effect of APOE and polygenic component on Alzheimer’s disease10.1016/j.neurobiolaging.2020.04.024 ↗
10. The role of neuropsychological assessment in the evaluation of patients with cognitive‐behavioral change due to suspected Alzheimer’s disease and other causes of cognitive impairment and dementia10.1002/alz.14363 ↗
11. The use of neuroimaging techniques in the early and differential diagnosis of dementia10.1038/s41380-023-02215-8 ↗
12. Alzheimer disease biomarkers: moving from CSF to plasma for reliable detection of amyloid and tau pathology10.1093/clinchem/hvad139 ↗
13. REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes10.1038/s41564-018-0295-3 ↗
14. The Amyloid-β pathway in Alzheimer’s disease10.1038/s41380-021-01249-0 ↗
15. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease10.1016/j.jalz.2011.03.003 ↗
16. Rethinking the detection and diagnosis of Alzheimer’s disease: Outcomes of a European Brain Council project10.1016/j.nbas.2023.100093 ↗
17. Blood-based biomarkers of Alzheimer’s disease and incident dementia in the community10.1038/s41591-025-03605-x ↗
18. Alzheimer’s Disease10.1056/NEJMra0909142 ↗
19. NIA‐AA research framework: toward a biological definition of Alzheimer’s disease10.1016/j.jalz.2018.02.018 ↗
20. The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy10.1016/j.ebiom.2016.03.035 ↗
21. The cellular phase of Alzheimer’s disease10.1016/j.cell.2015.12.056 ↗
22. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade10.1016/S1474-4422(09)70299-6 ↗
23. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics10.1038/nrd3505 ↗
24. A protein factor essential for microtubule assembly10.1073/pnas.72.5.1858 ↗
25. Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future10.1038/s41392-023-01484-7 ↗
26. Neuroinflammation in Alzheimer’s disease10.1016/S1474-4422(15)70016-5 ↗
27. Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation10.1186/s12974-023-02853-3 ↗
28. Oligomer Formation of Tau Protein Hyperphosphorylated in Cells10.1074/jbc.M114.611368 ↗
29. Brain-derived tau oligomer polymorphs: distinct aggregations, stability profiles, and biological activities10.1038/s42003-025-07499-w ↗
30. A state of delirium: deciphering the effect of inflammation on tau pathology in Alzheimer’s disease10.1016/j.exger.2016.12.006 ↗
31. From plaques to pathways in Alzheimer’s disease: the mitochondrial-neurovascular-metabolic hypothesis10.3390/ijms252111720 ↗
32. Prion-like spreading in tauopathies10.1016/j.biopsych.2017.04.003 ↗
33. Innate immunity in the central nervous system10.1172/JCI58644 ↗
34. Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition10.1523/JNEUROSCI.3442-16.2017 ↗
35. Astrocytes and microglia in neurodegenerative diseases: Lessons from human in vitro models10.1016/j.pneurobio.2020.101973 ↗
36. Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer’s disease10.1038/s41467-025-60806-1 ↗
37. The neurotransmitter puzzle of Alzheimer’s: dissecting mechanisms and exploring therapeutic horizons10.1016/j.brainres.2024.148797 ↗
38. The role of glial cells in synaptic dysfunction: insights into Alzheimer’s disease mechanisms10.14336/AD.2023.0718 ↗
39. Neuroinflammation in Alzheimer’s disease: current progress in molecular signaling and therapeutics10.1007/s10753-022-01721-1 ↗
40. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics10.1126/science.1072994 ↗
41. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide10.1038/nrm2101 ↗
42. A sensitive and accurate recombinase polymerase amplification assay for detection of the primary bacterial pathogens causing bovine respiratory disease10.3389/fvets.2020.00208 ↗
43. Designing the next-generation clinical care pathway for Alzheimer’s disease10.1038/s43587-022-00269-x ↗
44. Molecular genetics of early‐onset Alzheimer’s disease revisited10.1016/j.jalz.2016.01.012 ↗
45. Clinical trial endpoints and their clinical meaningfulness in early stages of Alzheimer’s disease10.14283/jpad.2022.41 ↗
46. A scoping review of remote and unsupervised digital cognitive assessments in preclinical Alzheimer’s disease10.1038/s41746-025-01583-5 ↗
47. Cognitive decline assessment in speakers of understudied languages
48. Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer’s disease randomized controlled trials
49. Amyloid imaging: past, present and future perspectives10.1016/j.arr.2016.01.005 ↗
50. PET imaging of tau deposition in the aging human brain10.1016/j.neuron.2016.01.028 ↗
51. MRI in the clinical management of Alzheimer’s disease: from early detection to therapy guidance10.1007/s40134-025-00435-0 ↗
52. Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease10.1093/brain/awad428 ↗
53. A literature review of MRI techniques used to detect amyloid-beta plaques in Alzheimer’s disease patients10.21037/apm-21-825 ↗
54. From cerebrospinal fluid to blood: the third wave of fluid biomarkers for Alzheimer’s disease10.3233/JAD-179926 ↗
55. Time to diagnosis in dementia: a systematic review with meta‐analysis10.1002/gps.70129 ↗
56. Machine learning in point-of-care testing: innovations, challenges, and opportunities10.1038/s41467-025-58527-6 ↗
57. CRISPR-based strategies for sample-to-answer monkeypox detection: current status and emerging opportunities10.1088/1361-6528/ad892b ↗
58. Biosensors as diagnostic tools in clinical applications
59. Opportunities and challenges in implementing CRISPR-based point-of-care testing for Monkeypox detection10.1080/07366205.2025.2473827 ↗
60. Electrochemical protein biosensors for disease marker detection: progress and opportunities10.1038/s41378-024-00700-w ↗
61. A microfluidic approach for hemoglobin detection in whole blood10.1063/1.4997185 ↗
62. Portable electrochemical micro-workstation platform for simultaneous detection of multiple Alzheimer’s disease biomarkers10.1007/s00604-022-05199-4 ↗
63. Evaluation of the GEM® Premier™ 4000: a compact blood gas CO-Oximeter and electrolyte analyzer for point-of-care and laboratory testing10.1515/CCLM.2008.043 ↗
64. SLIDE: saliva-based SARS-CoV-2 self-testing with RT-LAMP in a mobile device10.1021/acssensors.2c01023 ↗
65. Lateral flow test engineering and lessons learned from COVID-1910.1038/s44222-022-00007-3 ↗
66. Integrated ultrasound‐enrichment and machine learning in colorimetric lateral flow assay for accurate and sensitive clinical alzheimer’s biomarker diagnosis10.4028/b-wjQRP6 ↗
67. Quantitative assessment of AD markers using naked eyes: point-of-care testing with paper-based lateral flow immunoassay10.1186/s12951-021-01111-z ↗
68. Wearable chemical sensors for biomarker discovery in the omics era10.1038/s41570-022-00439-w ↗
69. Integrated Rayleigh wave streaming-enhanced sensitivity of shear horizontal surface acoustic wave biosensors10.1016/j.bios.2023.115944 ↗
70. A shape-code nanoplasmonic biosensor for multiplex detection of Alzheimer’s disease biomarkers10.1016/j.bios.2017.10.018 ↗
71. Quartz crystal microbalance as a holistic detector for quantifying complex organic matrices during liquid chromatography: 1. Coupling, characterization, and validation10.1021/acs.analchem.3c05440 ↗
72. THz biosensing applications for clinical laboratories: Bottlenecks and strategies10.1016/j.trac.2023.117057 ↗
73. Magnetoelastic resonance sensors: principles, applications, and perspectives10.1021/acssensors.2c00032 ↗
74. Planar single and dual-resonant microwave biosensors for label-free bacteria detection10.1016/j.snb.2021.130899 ↗
75. Printed electrochemical strip for the detection of miRNA-29a: a possible biomarker related to Alzheimer’s disease10.1021/acs.analchem.2c03542 ↗
76. Highly sensitive/selective 3D nanostructured immunoparticle-based interface on a multichannel sensor array for detecting amyloid-beta in Alzheimer’s disease10.7150/thno.25625 ↗
77. Portable vertical graphene@Au-based electrochemical aptasensing platform for point-of-care testing of tau protein in the blood10.3390/bios12080564 ↗
78. Innovative label-free lymphoma diagnosis using infrared spectroscopy and machine learning on tissue sections10.1038/s42003-024-07111-7 ↗
79. Hyperspectral imaging benchmark based on machine learning for intraoperative brain tumour detection10.1038/s41698-023-00475-9 ↗
80. Label-free optical biosensing: going beyond the limits10.1039/D3CS00155E ↗
81. Ultrasensitive detection of amyloid-β using cellular prion protein on the highly conductive au nanoparticles–poly(3,4-ethylene dioxythiophene)–poly(thiophene-3-acetic acid) composite electrode10.1021/acs.analchem.9b02266 ↗
82. Fluorescence-based portable assays for detection of biological and chemical analytes10.3390/s23115053 ↗
83. Compact multiplex PCR device for HIV-1 and HIV-2 viral load determination from finger-prick whole blood in resource-limited settings10.1016/j.bios.2024.116997 ↗
84. Rapid simultaneous self-testing of HIV and HCV viral loads with integrated RNA extraction and multiplex RT-PCR in under 1 h10.1016/j.bios.2025.117843 ↗
85. Multiplexed salivary miRNA quantification for predicting severe COVID-19 symptoms in children using ligation-RPA amplification assay10.1021/acssensors.5c01275 ↗
86. Learning from the EHR to implement AI in healthcare10.1038/s41746-024-01340-0 ↗
87. Hydrogel micropost-based qPCR for multiplex detection of miRNAs associated with Alzheimer’s disease10.1016/j.bios.2017.10.039 ↗
88. Sensitive detection of multiple blood biomarkers via immunomagnetic exosomal PCR for the diagnosis of Alzheimer’s disease10.1126/sciadv.abm3088 ↗
89. A blood based 12-miRNA signature of Alzheimer disease patients10.1186/gb-2013-14-7-r78 ↗
90. Advances in multiplex PCR for Alzheimer’s disease diagnostics targeting CDK genes10.1016/j.neulet.2021.135715 ↗
91. Isothermal amplification of nucleic acids: the race for the next “gold standard10.3389/fsens.2021.752600 ↗
92. Recent uses of paper microfluidics in isothermal nucleic acid amplification tests10.3390/bios13090885 ↗
93. Enzyme-assisted nucleic acid amplification in molecular diagnosis: a review10.3390/bios13020160 ↗
94. Isothermal amplification-assisted diagnostics for COVID-1910.1016/j.bios.2022.114101 ↗
95. A dual-signal amplification strategy based on rolling circle amplification and APE1-assisted amplification for highly sensitive and specific miRNA analysis for early diagnosis of alzheimer’s disease10.1016/j.talanta.2024.125747 ↗
96. Rolling circle amplification: a versatile tool for chemical biology, materials science and medicine10.1039/c3cs60439j ↗
97. Fluorescence detection of the genetic risk factor ApoE4 gene associate with Alzheimer’s disease based on a CRISPR-Cas12a system10.1016/j.microc.2025.112831 ↗
98. CRISPR-powered aptasensor for diagnostics of Alzheimer’s disease10.1021/acssensors.3c02167 ↗
99. Biological properties and DNA nanomaterial biosensors of exosomal miRNAs in disease diagnosis10.1039/D4SD00373J ↗
100. Sample-to-answer salivary miRNA testing: New frontiers in point-of-care diagnostic technologies10.1002/wnan.1969 ↗